LB073
BASELINE PROFILE OF MALNOURISHED OR AT-RISK PATIENTS WITH TYPE 2 DIABETES IN MULTICENTER RWE STUDY OF DIABETES-SPECIFIC ORAL NUTRITIONAL SUPPLEMENTATION IN SPAIN: THE STARLIGHT STUDY
A. Jiménez Sánchez1,*, S. Palma2, P. P. García Luna1, J. M. Garcia-Almeida3, L. Mola2, M. Lainez4, P. L. De Pablos5, J. F. Merino6, A. J. Martinez1, S. Jimenez7, C. Montalban8, M. I. Rebollo9, P. Matia10, L. Suarez11, A. Artero12, M. Blanco13, M. Layola13
1Hospital Universitario Virgen del Rocío, Sevilla, 2Hospital Universitario La Paz, Madrid, 3Hospital Universitario Virgen de la Victoria, Málaga, 4Hospital Universitario Virgen de la Macarena, Sevilla, 5Hospital Universitario Doctor Negrín, Gran Canaria, 6Hospital Universitario la Fe, Valencia, 7Hospital Universitario La Princesa, Madrid, 8Hospital Universitario Marqués de Valdecilla, Santander, 9Hospital Universitario Juan Ramon Jimenez, Huelva, 10Hospital Clinico San Carlos, Madrid, 11Hospital Universitario Central de Asturias, Asturias, 12Hospital General de Valencia, Valencia, 13Nestle Health Science, Esplugues de Llobregat, Spain
Rationale: Malnutrition, common in type 2 diabetes (T2DM), is associated with poor clinical and functional outcomes. Identifying at-risk patients for oral nutritional supplementation is relevant in practice. Diabetes-specific formulas may improve nutritional status while maintaining metabolic control; however, real-world evidence is limited, and ESPEN calls for further clinical studies.
Methods: Ongoing multicenter prospective RW study (12 hospitals) including adults with T2DM or drug-induced diabetes, malnourished/at risk (GLIM/MUST), initiating Meritene® Clinical Diabet Plus (Nov 2025–July 2026). Assessments at baseline, 3, and 6 months include clinical, metabolic, nutritional, functional, quality of life (QoL) and costs. Predefined interim analysis.
Results: To date 121 patients included (~330 planned) (Image 1). Despite 61.2% having normal weight,93.4% were malnourished (moderate/high risk), characterized by >10% weight loss (38%), low muscle mass (81.8%), reduced intake (83%), and inflammation (81%). Comorbidities were present in 92.6% (neoplasms 69.6%).
Bioimpedance and ultrasound were available in 120 and 103 patients respectively, suggesting impaired nutritional status with altered fluid distribution, borderline low muscle mass, and a predominance of visceral adiposity. In the prior 6 months, 38.8% were hospitalized (mean 20.6 days) and 51.2% went to emergency room.
Image 1. Population description
CRP: C-reactive protein
Image:
Conclusion: These baseline data describe T2DM malnourished/at-risk patients in routine practice, highlighting a clinically complex population with relevant nutritional impairment and supporting the role of diabetes-specific nutritional interventions.
Disclosure of Interest: A. Jiménez Sánchez Grant / Research Support from: The study was funded by Nestlé Health Science, which had no role in the study conduct or analysis., S. Palma Grant / Research Support from: The study was funded by Nestlé Health Science, which had no role in the study conduct or analysis., P. P. García Luna Grant / Research Support from: The study was funded by Nestlé Health Science, which had no role in the study conduct or analysis., J. M. Garcia-Almeida Grant / Research Support from: The study was funded by Nestlé Health Science, which had no role in the study conduct or analysis., L. Mola Grant / Research Support from: The study was funded by Nestlé Health Science, which had no role in the study conduct or analysis., M. Lainez Grant / Research Support from: The study was funded by Nestlé Health Science, which had no role in the study conduct or analysis., P. L. De Pablos Grant / Research Support from: The study was funded by Nestlé Health Science, which had no role in the study conduct or analysis., J. F. Merino Grant / Research Support from: The study was funded by Nestlé Health Science, which had no role in the study conduct or analysis., A. J. Martinez Grant / Research Support from: The study was funded by Nestlé Health Science, which had no role in the study conduct or analysis., S. Jimenez Grant / Research Support from: The study was funded by Nestlé Health Science, which had no role in the study conduct or analysis., C. Montalban Grant / Research Support from: The study was funded by Nestlé Health Science, which had no role in the study conduct or analysis., M. I. Rebollo Grant / Research Support from: The study was funded by Nestlé Health Science, which had no role in the study conduct or analysis., P. Matia Grant / Research Support from: The study was funded by Nestlé Health Science, which had no role in the study conduct or analysis., L. Suarez Grant / Research Support from: The study was funded by Nestlé Health Science, which had no role in the study conduct or analysis., A. Artero Grant / Research Support from: The study was funded by Nestlé Health Science, which had no role in the study conduct or analysis., M. Blanco Other: Employee of Nestle Health Science, sponsor of the study., M. Layola Other: Employee of Nestle Health Science, sponsor of the company.